<DOC>
	<DOC>NCT00722384</DOC>
	<brief_summary>To establish the tolerability and preliminary efficacy of Cand5 by a single intravitreal injection in patients with wet age-related macular degeneration.</brief_summary>
	<brief_title>Open Label Study for the Evaluation of Tolerability of Five Dose Levels of Cand5</brief_title>
	<detailed_description />
	<mesh_term>Macular Degeneration</mesh_term>
	<criteria>Patients with subfoveal predominantly classic, minimally classic and purely occult lesions, secondary to age related macular degeneration, with a total lesion size (including blood, atrophy/scar and neovascularization) of &lt; 12 total disc areas, of which at least 50% are active CNV. Patients must have visual acuity 20/50 to 20/320 in the study eye. Patients must have better visual acuity in the fellow eye than the study eye. Subretinal hemorrhage (if any) must comprise no more than 50% of total lesion size. Patients with concomitant eye disease, including glaucoma, uveitis, diabetic retinopathy, presence of pigment epithelial tears or rips, acute ocular or periocular infection in the study eye. Patients with &gt; 3 prior PDT treatments with Visudyne in the study eye. Patients who received PDT in the study eye within eight weeks prior to the baseline angiography/photography.</criteria>
	<gender>All</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2008</verification_date>
	<keyword>AMD</keyword>
	<keyword>Macular Degeneration</keyword>
	<keyword>Opko Health</keyword>
	<keyword>Acuity Pharmaceuticals</keyword>
	<keyword>bevasiranib</keyword>
	<keyword>Cand5</keyword>
	<keyword>Age-Related</keyword>
</DOC>